This breakthrough treatment is redefining weight loss, helping individuals to lose weight sustainably and reclaim their confidence
Review the current format, listed amount, price, stock state, and research-use-only policy before adding it to cart
Currently, the FDA has approved three different GLP-1s for the long-term treatment of obesity: Liraglutide (Saxenda), Semaglutide (Wegovy), and Tirzepatide (Zepbound)
For more details, please read the Terms & Conditions.
Place a rack in the center of your oven and preheat to 350 degrees F
It is critical to understand the difference between compounded and brand-name GLP-1 medications: Brand-name medications (Wegovy, Zepbound) are FDA-approved, manufactured under strict quality controls, and have been tested in large-scale clinical trials Compounded versions are not FDA-approved, meaning they have not undergone the same safety and efficacy testing In 2025, the FDA declared the shortage over, meaning compounding of semaglutide and tirzepatide is no longer legally permitted for most pharmacies Some compounded products have used different salt forms of semaglutide (such as semaglutide acetate instead of semaglutide sodium) that have not been shown to behave identically in the body Who Is a Good Candidate for GLP-1 Weight Loss Medication